Seagen Highlights First Solid Tumor Data For An ADCETRIS Immunotherapy Combination And Preclinical Data For Novel CD30-Directed Antibody-Drug Conjugate At Society For Immunotherapy Of Cancer Annual Meeting
Seagen Highlights First Solid Tumor Data For An ADCETRIS Immunotherapy Combination And Preclinical Data For Novel CD30-Directed Antibody-Drug Conjugate At Society For Immunotherapy Of Cancer Annual Meeting
Seagen 在癌症免疫治疗学会年会上重点介绍了 ADCETRIS 免疫疗法组合的首批实体瘤数据和新型 CD30 抗体药物偶联物的临床前数据
– Initial Phase 2 data presented for ADCETRIS in combination with immunotherapy pembrolizumab in metastatic non-small cell lung cancer and metastatic cutaneous melanoma –
— 已公布ADCETRIS联合免疫疗法pembrolizumab治疗转移性非小细胞肺癌和转移性皮肤黑色素瘤的第二阶段初始数据 —
– Preclinical data presented for novel antibody-drug conjugate SGN-35T –
— 提供了新型抗体药物偶联物 SGN-35T 的临床前数据 —
Seagen Inc. (NASDAQ:SGEN) today announced the first presentation of data evaluating ADCETRIS (brentuximab vedotin) in combination with an anti-PD-1 checkpoint inhibitor in non-small cell lung cancer (NSCLC) and melanoma, and shared preclinical data for an investigational CD30-directed antibody-drug conjugate (ADC) that uses a novel tripeptide linker. The studies were presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place November 3-5, 2023, in San...
希根公司（纳斯达克股票代码：SGEN）今天宣布首次公布评估ADCETRIS（brentuximab vedotin）与抗PD-1检查点抑制...
登录免费看全文
登录/注册